Paper Review Records
All Paper Review Records
24 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
In Utero Exposure to Acetazolamide and Pregnancy Outcomes: A Cohort Study
Camille Reinaud; Maria Hoeltzenbein; Valérie Touitou; Catherine Vauzelle; Elisabeth Elefant; Delphine Beghin; Benoît Marin; Bénédicte CoulmShow moreShow less
1. AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France; 2. Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany; 3. Limbach Genetics MVZ Humangenetik Bremen, Bremen, Germany; 4. Sorbonne Université, Hôpital Pitié-Salpêtrière, Département d’Ophtalmologie, 75013 Paris, France; 5. Sorbonne Université, INSERM, Institut Pierre-Louis d’Épidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département de Santé Publique, Centre de Référence sur les Agents Tératogènes (CRAT), 75013 Paris, France; 6. Département Universitaire de Maïeutique, Sorbonne Université, Paris, FranceShow moreShow less
Medication-Related Osteonecrosis of the Jaw: An Unmasking Disproportionality Analysis of VigiBase, the WHO Spontaneous Reporting Database
Elena Arzenton; Antonia Marcianò; Federico Gozzi; Domenico Levita; Francesco Maccarrone; Ugo Moretti; Fabio Scapini; Gianluca Trifirò; Giacomo Oteri; Marco TuccoriShow moreShow less
1. Department of Diagnostics and Public Health, Section of Pharmacology, University of Verona, Verona, Italy; 2. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, ItalyShow moreShow less
Discontinuation of Additional Risk Minimisation Measure Tools Implemented at Authorisation for Centrally Authorised Medicinal Products in the EU
Sharon C. M. Essink; Inge M. Zomerdijk; Valerie Strassmann; Thomas Goedecke; Sabine M. J. M. Straus; Helga Gardarsdottir; Marie L. De BruinShow moreShow less
1. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands; 2. Department of Pharmacovigilance, Medicines Evaluation Board, Utrecht, The Netherlands; 3. European Medicines Agency, Amsterdam, The Netherlands; 4. Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, The Netherlands; 5. Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, IcelandShow moreShow less
Understanding the Relationship between Causality Assessment and Drug Labeling Practices: An Evaluation of US Regulations and FDA Policy Documents
Sarah Tanveer; Wendy Camelo Castillo; Linda Wastila; Tarek A. Hammad; Catherine E. Cooke; John P. A. Ioannidis; Peter DoshiShow moreShow less
1. Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, USA; 2. Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, USA; 3. Medical Safety for Marketed Products Development, Plasma-Derived Therapies, Medical Devices, and Vaccines, Takeda Development Center Americas, Inc., Cambridge, USA; 4. Departments of Medicine and of Epidemiology and Population Health, Stanford University, Stanford, USAShow moreShow less
Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal
Michele Fusaroli; Joana Félix China; D. Sartori; Valentina Giunchi; Linda Härmark; Joep Scholl; Florence van Hunsel; G. Niklas Norén; Johan ElleniusShow moreShow less
1. Uppsala Monitoring Centre, Uppsala, Sweden; 2. Drug Safety Research Unit, Southampton, UK; 3. Netherlands Pharmacovigilance Centre Lareb, MH’s-Hertogenbosch, The Netherlands; 4. Department of PharmacoTherapy, Epidemiology, and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The NetherlandsShow moreShow less
EudraScore: Modification of the Vigi4Eudra-score for the Assessment of the Completeness of Adverse Drug Reaction Reports in EudraVigilance
Diana Dubrall; Patrick Christ; Dennis Lex; Robert Hoffmann; Thomas Grüger; Matthias Schmid; Bernhardt SachsShow moreShow less
1. University of Bonn, University Hospital Bonn, Institute for Medical Biometry, Informatics and Epidemiology, Bonn, Germany; 2. Research Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany; 3. Pharmacovigilance Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany; 4. Department for Dermatology and Allergy, University Hospital RWTH Aachen, Aachen, GermanyShow moreShow less
FAQ
How long does DRUG SAFETY take to review a manuscript?
As of 2026-11-18, CrushSCI has 24 complete review records for DRUG SAFETY. The fastest paper went from submission to acceptance in 4 days (ISoP MENA Chapter: Strategic Development and Future Directions Following a Decade of Strengthening Pharmacovigilance in the Middle East and North Africa, received 2026-08-16, accepted 2026-08-20); the slowest took 288 days. The average is 126.8 days and the median is 119 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
